JP2023525579A5 - - Google Patents

Info

Publication number
JP2023525579A5
JP2023525579A5 JP2022569101A JP2022569101A JP2023525579A5 JP 2023525579 A5 JP2023525579 A5 JP 2023525579A5 JP 2022569101 A JP2022569101 A JP 2022569101A JP 2022569101 A JP2022569101 A JP 2022569101A JP 2023525579 A5 JP2023525579 A5 JP 2023525579A5
Authority
JP
Japan
Prior art keywords
cells
class
vaccine
composition according
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022569101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525579A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032229 external-priority patent/WO2021231712A1/en
Publication of JP2023525579A publication Critical patent/JP2023525579A/ja
Publication of JP2023525579A5 publication Critical patent/JP2023525579A5/ja
Pending legal-status Critical Current

Links

JP2022569101A 2020-05-15 2021-05-13 低免疫原性の細胞および免疫応答におけるそれらの使用 Pending JP2023525579A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063025351P 2020-05-15 2020-05-15
US63/025,351 2020-05-15
PCT/US2021/032229 WO2021231712A1 (en) 2020-05-15 2021-05-13 Hypoimmunogenic cells and uses thereof in immune responses

Publications (2)

Publication Number Publication Date
JP2023525579A JP2023525579A (ja) 2023-06-16
JP2023525579A5 true JP2023525579A5 (https=) 2024-05-22

Family

ID=78525039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569101A Pending JP2023525579A (ja) 2020-05-15 2021-05-13 低免疫原性の細胞および免疫応答におけるそれらの使用

Country Status (4)

Country Link
US (1) US20230338533A1 (https=)
EP (1) EP4149525A4 (https=)
JP (1) JP2023525579A (https=)
WO (1) WO2021231712A1 (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
CA3205636A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
FI2838548T3 (fi) * 2012-04-17 2023-10-02 Univ Washington Through Its Center For Commercialization HLA:n luokan II puutteelliset solut, HLA:n luokan II puutteelliset solut, jotka kykenevät ilmentämään HLA:n luokan II proteiineja, ja niiden käytöt
CN107921148A (zh) * 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
EP3423580A1 (en) * 2016-03-04 2019-01-09 Editas Medicine, Inc. Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
KR102030364B1 (ko) * 2016-12-02 2019-10-10 가톨릭대학교 산학협력단 멀티플렉스 CRISPR-Cas9 시스템을 이용한 HLA 결핍 세포주로부터 제조된 인공항원제시세포 및 이의 용도
JP2020505025A (ja) * 2017-01-13 2020-02-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
WO2019136038A1 (en) * 2018-01-02 2019-07-11 Khloris Biosciences, Inc. Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer
KR102304549B1 (ko) * 2018-05-30 2021-09-27 주식회사 강스템바이오텍 Hla 유전자가 제거된 인간 유도만능줄기세포 유래 중간엽줄기세포 및 그의 제조 방법
WO2020018620A1 (en) * 2018-07-17 2020-01-23 The Regents Of The University Of California Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells
CA3109078A1 (en) * 2018-07-17 2020-01-23 The Regents Of The University Of California Cells differentiated from immunoengineered pluripotent cells
KR20210128440A (ko) * 2019-02-15 2021-10-26 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 범용 공여자 줄기 세포 및 관련 방법
EP4138893A4 (en) * 2020-04-21 2024-06-12 Intima Bioscience, Inc. CELLULAR VACCINE PLATFORM AND METHODS OF USE THEREOF

Similar Documents

Publication Publication Date Title
CY1110525T1 (el) Βελτιστοποιημενη εκφραση της hpv 45 li σε ζυμη
JP2025023916A5 (https=)
CN114729373B (zh) 一种新型冠状病毒mRNA疫苗及其制备方法与应用
JP2022549791A5 (https=)
CN118750594B (zh) 一种二价猪口蹄疫mRNA疫苗及其制备方法和应用
WO2023035372A1 (zh) 一种有限自我复制mRNA分子系统、制备方法及应用
IL319667A (en) Bispecific recombinant antibodies targeting TSLP and IL4R
WO2023227124A1 (zh) 一种构建mRNA体外转录模板的骨架
CN116041448A (zh) 新型冠状病毒免疫原性物质、其制备方法和应用
WO2005021713A8 (en) Vectors expressing sars immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
WO2011039646A2 (en) Papilloma virus -like particles for targeted gene delivery
CN118206622A (zh) RSV融合前F蛋白的突变体、核酸及mRNA疫苗
CN115944722A (zh) 一种抗肿瘤mRNA疫苗及其制备方法和应用
JP2023525579A5 (https=)
CN115845043A (zh) 一种模板DNA分子及其在制备mRNA和疫苗中的应用
CN114903987A (zh) 一种用于治疗慢性乙型肝炎病毒感染的mRNA药物及其制备方法和应用
CN117838848A (zh) 一种口蹄疫二价mRNA疫苗及其制备方法和应用
ES8600938A1 (es) Un procedimiento para preparar el antigeno de superficie de la hepatitis b
CN115992152A (zh) 一种用于乙型肝炎病毒治疗性mRNA疫苗及其制备方法与应用
JP7555929B2 (ja) Ｂ型肝炎を治療するための薬物製剤、その製造方法及び用途
He et al. Self-assembling nanoparticles presenting receptor binding domain and stabilized spike as next-generation COVID-19 vaccines
CN111494618A (zh) 一种手性纳米材料佐剂的制备方法及其应用
WO2025118638A1 (zh) 一种肿瘤细胞膜超声微泡及其制备方法和在增强肿瘤免疫治疗中的应用
CN116904489A (zh) 一种鸭坦布苏病毒核酸疫苗及应用
CN112641935A (zh) 一种含颗粒载体的亚单位疫苗及其应用